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160Molecular diagnosis in vascular Ehlers-Danlos
syndrome predicts pattern of arterial involvement
and outcomes
Sherene Shalhub, MD, MPH,a James H. Black III, MD,b Alana C. Cecchi, MS,c Zhi Xu, PhD,d
Ben F. Griswold, BS,d Hazim J. Saﬁ, MD,e Dianna M. Milewicz, MD, PhD,c and
Nazli B. McDonnell, MD, PhD,d Seattle, Wash; Baltimore, Md; and Houston, Tex
Objective: The management of arterial pathology in individuals with vascular Ehlers-Danlos syndrome (vEDS) remains a
challenge. Here we describe the correlation between COL3A1 gene mutation type and the clinical phenotype in individuals
with vEDS.
Methods: Individuals with conﬁrmed molecular diagnoses of vEDS were enrolled in a multi-institutional natural history
study. Data collected included demographics, clinical and family histories, arterial pathology (aneurysm, dissection, and
rupture), operative details, and autopsy reports. Individuals were classiﬁed into two cohorts by the type of COL3A1
mutations and their effect on the amount of normal collagen produced: those with mutations that lead to minimal (MIN)
production (10%-15%) of normal type III collagen and those with haploinsufﬁciency (HI) mutations that lead to pro-
duction of 50% of the normal type III collagen.
Results: A cohort of 68 individuals (72%) from 56 families had arterial pathology (44% male) with 13% HI. The HI group
was older at the time of their ﬁrst vascular event (mean, 42 [range, 26-58] years vs 33 [range, 8-62] years; P[ .016) and
had a higher incidence of aortic pathology than the MIN group (56% vs 21%; P[ .025). Visceral arterial pathology was
seen in 43 arteries in 23 individuals in the MIN group vs only one artery in ﬁve individuals in the HI group. Emergency
surgical procedures were more likely to be undertaken when vEDS diagnosis was not known (81% vs 41%; P[ .005), and
81% of these procedures were open surgical repair compared with 19% endovascular repairs (P [ .019). Open and
endovascular repairs were equally used in the elective setting. Postoperative complications were highest when the
diagnosis of vEDS was not known (62% vs 14%; P < .001) and when procedures were undertaken in an emergency
setting (5% vs 55% P < .001). Mortality due to arterial complications was 0% in the HI cohort and 21% in the MIN
cohort (P [ .132).
Conclusions: Arterial pathology in vEDS individuals is related to the underlying COL3A1 mutation type. The arterial
pathology in individuals with HI mutations occurs at later ages with a higher incidence of aortic disease compared
with other COL3A1 mutation types. Molecular diagnosis is recommended because diagnosis conﬁrmation, appro-
priate surveillance, and prophylactic interventions in an elective setting improve surgical outcomes. (J Vasc Surg
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://dx.doi.org/10.1016/j.jvs.2014.01.070Vascular Ehlers-Danlos syndrome (vEDS) is a syn-
drome inherited in an autosomal-dominant manner that
leads to spontaneous arterial dissection or rupture. Man-
agement of these arterial complications remains a chal-
lenge. The disorder is due to heterozygous mutations in
COL3A1, which encodes the procollagen peptide for
type III collagen.1 Type III collagen is especially abundant
in the skin, blood vessels, and hollow organs such as the
bowel and uterus. The complications of vEDS reﬂect the
expression pattern of the gene and include rupture and
dissection of primarily medium-sized arteries, spontaneous
rupture of the intestine or the gravid uterus, and thin, frag-
ile skin that bruises easily and heals poorly.
Although the estimated minimum prevalence is one in
200,000,2 vEDS diagnosis is increasing due to improve-
ments in molecular diagnosis and recognition of mutations
that lead to a milder phenotype. More than 700 COL31A
mutations have been identiﬁed, with 50% of affected indi-
viduals inheriting the mutation from an affected parent,
and 50% due to de novo mutations.2,3
Two-thirds of the COL3A1 mutations are caused by
“mis-sense mutations,” which are glycine substitutions in
Fig 1. Spectrum of facial features in individuals with vascular Ehlers-Danlos syndrome (vEDS) shows variability among
patients and does not necessarily correlate with the severity of the underlying arterial pathology. These four individuals
died of vascular complications. A, Caucasian man (MIN mutation, c.2553þ1delG) presenting with characteristic vEDS
facies, including proptotic eyes, long and thin nose, minimal subcutaneous facial fat, and a triangular-shaped face.
B, Hispanic woman (MIN mutation, c.3545G>A p.G1182E) with mildly proptotic eyes, a long thin nose, and a
hypotrophic forehead scar, but otherwise normal facial features. C, Caucasian man (MIN mutation, c.2870G>T,
p.G957D) with downslanting palpebral ﬁssures, long thin nose, thin lips, and attached pinna. D, Caucasian woman
(c.665G>T, p.G222V) presenting with a long thin nose but otherwise normal facial features. Written consent was
obtained at the time of enrollment for clinical photography and use in medical education.MIN,Mutations that lead to
minimal (10%-15%) normal type III collagen production. Consent to have their images published in JVS was obtained
for all patients shown.
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COL3A1 mutations are caused by “exon skip mutations”
that lead to exon splicing errors that cause an in-frame shift
in the reading frame for translation.5 Both types of mutation
lead to equal production of abnormal and normal procolla-
gen peptides, but because type III collagen is a homotrimer
of three identical procollagen peptides, such mutations lead
to production of a seven-to-one ratio of abnormal to normal
collagen molecules, thus a minimal (MIN) amount (10%-
15%) of normal collagen is produced.3,6The remainder of the COL3A1 mutations are non-
sense mutations or frameshift mutations that lead to the
creation of premature termination codons. These prema-
ture stops in translation cause rapid degeneration of the
mutant messenger RNA by way of non-sense-mediated
decay. This causes expression of a single gene, thus termed
haploinsufﬁciency (HI). The end result is production of
50% of the amount of normal type III procollagen. HI mu-
tations are associated with reduced penetrance and delayed
onset of arterial pathology compared with MINmutations.7
Fig 2. Cutaneous manifestations of vascular Ehlers-Danlos syndrome (vEDS). A, Thin, translucent skin with visible
venous pattern on the lower back of a patient with vEDS (MIN mutation, exon skip). B, Widened atrophic scar in a
patient (HI mutation) after open abdominal aortic aneurysm repair. HI, Haploinsufﬁciency mutations that lead to 50%
normal type III collagen production; MIN, mutations that lead to minimal (10%-15%) normal type III collagen
production.
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ment of vEDS-associated arterial pathology at tertiary
referral centers and to correlate presentation and outcome
with the underlying type of mutation.METHODS
Approval by the Institutional Review Board was
obtained to enroll individuals with vEDS referred to the
University Texas at Houston Medical School, Johns Hop-
kins Hospital, and the National Institute on Aging (NIA)
Studies of Heritable Disorders of Connective Tissue trial
(NCT00270686), which was approved by the MedStar
Institutional Review Board (#2003-086).
The cohort for this study comprised a subgroup of
enrolled individuals with a conﬁrmed molecular diagnosis
of vEDS with arterial pathology. Proper consents were ob-
tained from the patients, including written consents for
clinical photography and use in medical education. All
identiﬁable photographs in this report are from deceased
individuals who provided consents for use of their photo-
graphs at the time of enrollment.
Data collected were initially retrospective, and ongoing
longitudinal follow-up occurred from the date of enroll-
ment. Data were obtained from study visits, medical
records, radiology images, correspondence with referring
physicians, and telephone interviews. Abstracted data
included demographics, age at diagnosis, family history,
reasons for diagnosis, and clinical diagnostic criteria, as
deﬁned by the Revised Nosology of Villefranche.2 Arterial
pathology was deﬁned as arterial dissection, aneurysm,
and rupture. Data collected included initial age at arterial
presentation, surveillance and diagnostic imaging if per-
formed (computed tomography [CT], magnetic resonance
imaging, and duplex ultrasound scans), management,
morbidity, and mortality.Molecular diagnosis. COL3A1 mutation detection
was performed on a clinical basis in another laboratory
or on a research basis at the NIA. At the NIA, the coding
regions and ﬂanking sequences of the COL3A1 gene were
ampliﬁed and sequenced. Primers were designed by
Primer3 (http://frodo.wi.mit.edu/primer3/) and are
available upon request. Mutations were identiﬁed by align-
ment with the reference sequence (ENSG00000168542).
Data collected included the COL3A1 mutation causing
vEDS and biochemical analysis of type III procollagen
production by dermal ﬁbroblasts performed by a Clinical
Laboratory Improvement Amendments-certiﬁed labora-
tory. Results of dermal ﬁbroblasts studies were reviewed,
and the amount of type III procollagen produced was
veriﬁed to correspond with the underlying COL3A1 mu-
tation. The patients were divided into two groups: MIN
and HI based on the predicted effect, and in some cases,
proven effect, of COL3A1 mutations on type III pro-
collagen production.
Statistical analysis. Data were analyzed using Excel
2010 software (Microsoft Corp, Redmond, Wash) and
SPSS 20.0 software (IBM Corp, Armonk, NY). Data are
presented as mean6 standard error of the mean and ranges
or as numbers and percentages. Continuous variables were
compared using a two-sample t-test, assuming that variance
was equal. Categoric variables were compared using c2
testing. All P values were two-sided, and <.05 was
considered signiﬁcant.
RESULTS
Arterial pathology related to vEDS was documented in
68 individuals (44.1% male). The mean age at diagnosis
was 33.0 6 1.6 years (range, 0.3-63 years). Skin biopsies
were performed in 24 of the cohort (35.8%).
Family history. Clinical manifestations of vEDS were
reported in the family members of 44 of the 68 individuals
Table I. Demographics, clinical characteristics, and reasons for diagnosis in patients with vascular Ehlers-Danlos
syndrome (vEDS)
Variablesa All (N ¼ 67) MIN (n ¼ 58) HI (n ¼ 9) Pb
Male 30 (44.1) 23 (39.7) 7 (77.8) .032
Caucasian 60 (89.6) 51 (87.9) 9 (100.0)
African American and Hispanic 7 (10.4) 7 (12.1) 0
Age, years 40.9 (8-70.2) 39.9 (8 -70.2) 47.5 (26-61.6) .116
Age at
Diagnosis, years 33 (0.3-63) 31.5 (0.3-63) 42.6 (26-58) .016
First arterial pathology diagnosis, years 34.2 (8-62) 33.0 (8-62) 41.6 (26-58) .030
Major and minor criteria
Family history of vEDS 43 (64.2) 35 (60.3) 8 (88.9) .097
Easy bruising 51 (76.1) 46 (79.3) 5 (55.6) .120
Colon perforation 8 (11.9) 8 (13.8) 1 (1.7) .235
Gravid uterine rupture (females) 1 (2.7) 1 0
Thin translucent skin 38 (56.7) 36 (62.1) 7 (12.1) .025
Skin hyperextensibility 7 (10.4) 7 (12.1) 0 .271
Characteristic facial appearance 41 (61.2) 38 (65.5) 3 (33.3) .065
Carotid-cavernous sinus ﬁstula 4 (6) 4 (6.9) 0 .417
Small joint hypermobility 29 (43.3) 28 (48.3) 1 (11.1) .036
Tendon or muscle rupture 6 (9) 6 (10.3) 0 .312
Early-onset varicose veins 9 (13.4) 9 (15.5) 0 .204
Pneumothorax/hemothorax 15 (22.4) 14 (24.1) 1 (11.1) .383
Clubfoot 6 (9) 6 (10.3) 0 .312
Other comorbidities
Hypertension 15 (22.4) 11 (19) 4 (44.4) .088
Pyloric stenosis 3 (4.5) 3 (5.2) 0 .485
Shoulder surgery or dislocation 4 (6) 4 (6.9) 0 .417
Migraine headaches 6 (9) 6 (10.3) 0
Reason for diagnosis
Personal history of vascular pathology 29 (43.3) 22 (37.9) 7 (77.8) .025
Family history 21 (31.1) 19 (32.8) 2 (22.2)
Personal history of colon perforation 5 (7.5) 5 (8.6) 0
History of excessive bruising 4 (6) 4 (6.9) 0
Diagnosed at autopsy 2 (3) 2 (3.4) 0
History of excessive scarring 1 (1.5) 1 (1.7) 0
History of ruptured spleen 1 (1.5) 1 (1.7) 0
Strong phenotype 1 (1.5) 1 (1.7) 0
Unknown reason 2 (3) 2 (3.4) 0
HI, Haploinsufﬁciency mutations that lead to 50% normal type III collagen production; MIN, mutations that lead to minimal (10%-15%) normal type III
collagen production.
aCategoric data are presented as number (%) and continuous data as mean (range).
bThe P value was calculated using the Pearson c2 test for categoric data and by independent samples t-test with equal variances assumed for the continuous
variables.
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reported family histories, 15 (22.1%) had a family member
with a conﬁrmed molecular diagnosis of vEDS as indicated
by the presence of a COL3A1 mutation.
Mutation types. There were 59 individuals (86.8%)
with MIN mutations. MIN mutations included mis-sense
in 42 (61.8%), exon skip in 12 (17.6%), and unusual mu-
tations in 5 (7.4%). In addition, one individual had
biochemical diagnosis of minimal type III procollagen
production and was thus included in this group. There
were nine individuals (13.2%) with HI mutations,
including non-sense in ﬁve (55.6%) and frameshift muta-
tions in four (44.4%).
The HI group was older when the ﬁrst arterial pathol-
ogy was diagnosed (mean age, 41.6 6 2.9; range,
26-58 years) compared with the MIN group (33.1 6 1.5;
range, 8-62 years; P ¼ .030). Characteristic facialappearance was common (61.2%) but displayed a wide range
of variability (Fig 1). Easy bruising and the characteristic thin
translucent skin with visible veins (Fig 2) were seen more
commonly in the MIN group than in the HI group
(Table I). Table I details the demographics, clinical diag-
nostic criteria, and reasons for diagnosis of the vEDS cohort.
Arterial pathology. The distribution of arterial pathol-
ogy based on genotype is illustrated in Fig 3. Aorta
involvement was seen in 16 individuals. The prevalence of
aortic disease was signiﬁcantly higher in the HI group
(55.6%) than in the MIN group (7%; P < .001). Surgical
management and outcomes are detailed in Table II.
Nonoperative management was undertaken, without com-
plications, in a descending thoracic aorta aneurysm (3.5 cm)
that was diagnosed in a patient with MIN mutation.
Pathology of brachiocephalic arteries. Details of the
brachiocephalic arteries involved and management are
Fig 3. Arterial involvement in vascular Ehlers-Danlos syndrome
(vEDS) patients by COL3A1 mutations. Although vEDS involves
medium-sized arteries more commonly, there was an increased
prevalence of aortic involvement in the HI cohort compared with
the MIN cohort (P ¼ .025). CCF, Carotid cavernous ﬁstula; HI,
mutations that lead to 50% normal type III collagen production;
MIN, mutations that lead to minimal (10%-15%) normal type III
collagen production; SMA, superior mesenteric artery.
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involvement was seen in nine individuals, all with MIN
mutations.
Visceral arteries. Multivisceral arterial involvement
was seen in 23 patients (43 arteries), all in the MIN group.
In the HI group, there were ﬁve individuals with visceral
arterial involvement, all with single-artery pathology.
Celiac artery pathology occurred only in ﬁve individ-
uals with MIN mutation: three aneurysms (1.5-2 cm in
diameter) and two dissections that progressed to aneu-
rysms (1.6-1.8 cm) during 1 year of follow-up. All of these
individuals were managed nonoperatively.
Hepatic artery pathology occurred in 10 individuals
(seven MIN [12.1%] vs three HI [33.3%]; P ¼ .096). Man-
agement was nonoperative in six aneurysms smaller <2 cm
in diameter. Two individuals underwent coil emboliza-
tion to treat a right hepatic artery (2.2 cm in diameter)
and an intraparenchymal hepatic artery rupture. One indi-
vidual, a 34-year-old woman with MIN-type mutation(c.1772G>A, p.Gly591Asp), remains under observation
due to high surgical risk for a stable 3-cm proper hepatic
artery aneurysm.
Splenic artery pathology occurred in 18 individuals (17
MIN [29.3%] vs one HI [11.1%]; P ¼ .252). Management
was nonoperative in isolated dissections or in
aneurysms <1.7 cm in diameter (n ¼ six). Coil emboliza-
tion was performed successfully in four aneurysms >2 cm
in diameter (one with a contained rupture). A ruptured
splenic artery of unknown size with hemodynamic compro-
mise occurred in two female patients who required opera-
tive exploration and splenectomy. One was 62 years old
(c.3319G>C, p.Gly1107Arg), the other was 28 years old
(c.3499G>C, p.Gly1000Arg), and both had MIN-type
mutations and were diagnosed after the rupture event.
Superior mesenteric artery (SMA) pathology occurred
only in individuals with the MIN mutation. One patient,
a 20-year-old man (c.2482G>T, p. Gly828Trp), pre-
sented with rupture not amenable to repair, thus necessi-
tating ligation and right hemicolectomy. One patient
with SMA dissection was managed nonoperatively,
and another SMA dissection in a 39-year-old woman
(c.2356G>A, p.Gly786Arg) was managed by placement
of a 6-mm 18-mm bare metal stent. Initial attempt at ac-
cess through the brachial artery for intended embolization
was complicated by brachial artery dissection, necessitating
transfer to a tertiary center (Johns Hopkins Hospital). The
case was then performed through a femoral artery access,
with manual compression for 5F sheath removal, and no
adverse events.
Renal artery pathology occurred in 17 individuals (16
MIN [27.6%] vs one HI [11.1%]; P ¼ .291). This involved
small aneurysms and dissections in 14, leading to renal in-
farcts in eight, all managed nonoperatively. The renal artery
in a 41-year-old female patient who had undiagnosed
vEDS (c.766delA, p. Ile256Fx, HI type mutation) had
ﬁbromuscular dysplasia-type beaded appearance. She
underwent an attempted open repair, complicated by
nephrectomy and a subsequent incisional hernia. Coil
embolization was performed successfully in one patient
with an intra-parenchymal renal artery aneurysm, and on
subsequent follow-up was noted to have a dissection that
was treated with nonoperative management. A ruptured
renal artery with hemodynamic compromise occurred in a
17-year-old female patient (IVS43þ2T>G, MIN-type mu-
tation), who died intraoperatively of hemorrhagic shock.
Iliac arteries. Iliac arteries aneurysms and dissections
independent of abdominal aortic involvement occurred in
22 individuals (22 MIN [34.5%] vs two HI [22.2%];
P ¼ .466). Successful nonoperative management was
used in cases of dissection (n ¼ seven) aneurysms <2.5 cm
in diameter (n ¼ three). Details of iliac arteries operative
management are reported in Table IV. Two patients died
of presumed iliac artery rupture: one was a 28-year-old
woman (c.3201þ2T>C,MIN-type mutation) with a known
maximum iliac artery size of 1.4 cm, and the second was
a 29-year-old woman (c.665G>T, p.Gly222Val, MIN-
type mutation) with known iliac artery dissection. Both
Table II. Surgical management and outcomes of aortic pathology in patients with vascular Ehlers-Danlos
syndrome (vEDS)
Aortic pathology
Age,
years Sex Mutation Operation Outcome
Thoracic aorta
Type A aortic dissection 40 M HI Interposition graft, fem-fem bypass Graft infection
ATA and arch homograft
Type B aortic dissection with
extension into iliacs
35 M HI Endovascular stent graft Renal infarcts due to embolization,
alive at age 42
Chronic type B dissection with
6 cm DTA aneurysm
19 M MIN Reversed elephant trunk (Dacron)a Enlargement of intercostals patch
2 years later
Interposition Dacron graft, bypass
to celiac, SMA, and renal arteries
Alive at age 25
Abdominal aorta
AAA 40 M HI Aortobiiliac repair Iliac limb thrombosis, IH
Redo aortobiiliac bypass, Incisional
hernia repair
Abdominal wound dehiscence.
(Fig 2, B). Alive at age 52
AAA saccular (4 cm), bilateral
CIAA with dissection
58 M HI Aortobiiliac repair, jump graft
to RIIA
Alive at age 61
AAA, dissection, rupture 51 M HI Aortobiiliac repair; “buttery” aorta Alive at age 57
Abdominal aortic dissection
(trauma related) to RCFA with
RLE ischemia
24 M HI Fem-fem bypass Abdominal aorta at 3 cm.
Alive at age 32
AAA (4.6 cm) 41 M HI Interposition graft Alive at age 47
AAA, bilateral CIAA 21 F MIN Aortobiiliac repair, fragile tissue Abdominal wound dehiscence.
Died 10 years later
AAA (4.5 cm), bilateral CIAA
due to aortic dissection
(trauma related)
27 M MIN Aortobiiliac repair Alive at age 27
AAA, Abdominal aortic aneurysm; ATA, ascending thoracic aorta; CIAA, common iliac artery aneurysm; DTA, descending thoracic aorta; F, female; fem-fem,
femorofemoral;HI, haploinsufﬁciency mutations that lead to 50% normal type III collagen production; IH, intimal hyperplasia;M, male;MIN,mutations that
lead to minimal (10%-15%) normal type III collagen production; RCFA, right common femoral artery; RIIA, right internal iliac artery; RLE, right lower
extremity; SMA, superior mesenteric artery.
aDuPont, Wilmington, Del.
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nostic workup.
Effect preoperative diagnosis of vEDS on operative
outcomes. Fifty procedures (29 emergency, 21 elective)
were performed in 35 patients (nine HI [25.7%]) and
involved the brachiocephalic arteries in 9, coronary arteries
in 3, aorta in 12, iliac arteries in 8, visceral arteries in 14,
tibial arteries in 2, inferior epigastric artery in 1, and
ruptured chordae tendineae in 1. Emergency procedures
were performed in 62.2% of the MIN group and in
46.2% of the HI group. Postoperative complications were
similar between the MIN (13 [35.1%]) and HI (four
[30.7%]) groups (P ¼ .775)
Diagnosis of vEDS was known in 42% of individuals
before surgical intervention. Arterial repairs in these pa-
tients were approached in an elective manner with an equal
mix of open and endovascular repair, 48.4% and 51.7%,
respectively, as necessitated by the underlying arterial
pathology (Fig 4). In patients who required emergency in-
terventions, the surgical technique was altered to accom-
modate the fragility of tissues.
The patients with undiagnosed vEDS were signiﬁcantly
more likely to present in an emergency fashion (80.9% vs
41.3%; P ¼ .005) and undergo open surgical repair (81%
vs 48.3%; P ¼ .019). Postoperative complications were
substantially increased in these individuals (P < .001;Table V). All intraoperative deaths (n ¼ 3) occurred in in-
dividuals with the MIN-type mutation who presented in an
emergency fashion and required management without the
beneﬁt of a preoperative vEDS diagnosis.
Mortality. Mean follow-up from the time of diagnosis
was 8 6 0.82 years (range, 1-26 years). There were 12
deaths, all occurring in the MIN group (21%), with mean
age at death of 31.4 6 2.6 years (range, 17-45 years).
Causes of death were intraoperative deaths during attempts
to repair ruptured iliac arteries (n ¼ 2) and a renal artery
(n ¼ 1), stroke after carotid cavernous ﬁstula embolization
(n ¼ 1), mesenteric arterial thrombosis and necrosis after
admission for small-bowel obstruction (n ¼ 1; Fig 1, A),
central catheter insertion complication (n ¼ 1; Fig 1, B),
rapid aneurysmal degeneration of iliac and gluteal arteries
complicated by retroperitoneum and spontaneous hemo-
thorax after colostomy take down (n ¼ 1; Fig 1, C), pre-
sumed iliac artery rupture (n ¼ 2; Fig 1, D), and
unexpected death of unknown causes (n ¼ 3).
DISCUSSION
Management of vascular pathology associated with
vEDS remains a clinical challenge. This report highlights
the importance of establishing the molecular diagnosis in
cases of vEDS. Although clinical ﬁndings can offer a sug-
gestion of the diagnosis, molecular testing should be
Table III. Presentation, management, and complications of brachiocephalic arteries pathology in patients with vascular
Ehlers-Danlos syndrome (vEDS)
Artery
Arterial
pathology No.
Mutation
(No.)
Age
range,
years Presentation (No.) Management Complications/comments
Carotid Dissection 5 MIN (4),
HI (1)
26-51 Surveillance (2),
symptomatic (1),
trauma (2)
Nonoperative None
Stenosis 2 MIN (1),
HI (1)
36-41 Surveillance Nonoperative FMD appearance (HI)
Ectasia 3 MIN (2),
HI (1)
36-63 Surveillance Nonoperative None
Aneurysm 7 MIN 22-56 Surveillance (6),
Symptomatic (1)
Nonoperative (6),
coiling & stenting (1)
TIA after coiling
CCF 5 MIN 25-46 Symptomatic Endovascular One required repeat embolization
2 years later
Vertebral Dissection 6 MIN (5),
HI (1)
22-52 Surveillance (3),
symptomatic (3)
Nonoperative PCA infarct (age 52), stenosis on
F/U (n ¼ 2)
Ectasia 1 MIN 36 Surveillance Nonoperative None
Aneurysm 1 MIN 29 Surveillance Nonoperative 0.5 cm at V2
Dissection 2 MIN 41 Surveillance Nonoperative Bilateral in same case
Subclavian Ectasia 1 MIN 52 Surveillance Nonoperative None
Aneurysm 3 MIN 26-34 Surveillance Nonoperative (3) None
Aneurysm 1 MIN 26 Symptomatic R SCA ligation, L axillary
to R SCA bypass
Bypass thrombosis, reintervention,
alive at age 27
Aneurysm 1 MIN 18-32 Rupture (R SCA) Endovascular stenting
R CCA/R SCA
No complications
Aneurysm 1 MIN 32 Rupture (L SCA) Carotid subclavian bypass Post-op infarcts, prolonged
ventilator dependence,
tracheostomy
CCA, Common carotid artery; CCF, carotid-cavernous ﬁstula; FMD, ﬁbromuscular dysplasia; F/U, follow-up; HI, haploinsufﬁciency mutations that lead to
50% normal type III collagen production; L, left; MIN, mutations that lead to minimal (10%-15%) normal type III collagen production; PCA, posterior
cerebral artery; R, right; TIA, transient ischemic attack; SCA, subclavian artery.
Table IV. Iliac artery interventions and complications in cases of vascular Ehlers-Danlos syndrome (vEDS)
Pathology Mutation Age, years Management Complications
AVF/symptomatic MIN 28 Elective endovascular repair Alive at age 34
AVF/rupture MIN 28 Emergency open repair Intraoperative death
Dissection MIN 55 Elective prophylactic iliofemoral bypass Alive at age 59
Dissection MIN 43 Elective prophylactic iliofemoral bypass Alive at age 48
Aneurysm/dissection HI 27 Elective prophylactic aortobiiliac repair Alive at age 26
Dissection/rupture MIN 42 Emergency open repair Wound infection, alive at age 50
Aneurysm/rupture MIN 22 Emergency open repair Intraoperative death
AVF, Arteriovenous ﬁstula; HI, haploinsufﬁciency mutations that lead to 50% normal type III collagen production; MIN, mutations that lead to minimal
(10%-15%) normal type III collagen production.
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of the underlying molecular diagnosis and classifying the
mutation by the effect on type III collagen production
are important elements in the counseling and care of
vEDS patients. Furthermore, it differentiates vEDS from
other syndromes such as Loeys-Dietz syndrome, which
has a similar age at presentation and features that overlap
with vEDS patients.9 Molecular testing allows for critical
genotype-phenotype correlations to be identiﬁed, such
as the fact that patients with HI mutations present at an
older age, have milder arterial disease than those with
MIN mutations,7 and have a high prevalence of aortic
disease.Our data support that elective repair for arterial compli-
cations can be performed with acceptable morbidity. Given
the small cohort size, it is difﬁcult to set absolute guidelines
beyond what is currently recommended for patients
without vEDS. We propose elective interventions in
when rapid change, such as growth or dissection, occurs
in a previously stable aneurysm, and we individualize the
recommendations to the patient based on the risk/beneﬁt
proﬁle for each patient. Knowledge of the molecular diag-
nosis allows preoperative counseling and modiﬁcation of
the surgical techniques, which are critical to successful out-
comes. Patients with an established preoperative diagnosis
treated in an elective setting have signiﬁcantly improved
Fig 4. A 6-cm carotid artery aneurysm developed in a 34-year-old woman acutely in the postpartum period.
A, A three-dimensional computed tomography (CT) reconstruction and (B) representative axial image of a CT scan
demonstrate the large right internal carotid artery aneurysm. Her arterial pathology led to vascular Ehlers-Danlos
syndrome (vEDS) diagnosis (MIN mutation, c.1772G>A, p.Gly591Asp) and preoperative multidisciplinary plan-
ning accordingly. C, She was successfully treated with stent-assisted coil embolization of the internal carotid artery
aneurysm. MIN, mutations that lead to minimal (10%-15%) normal type III collagen production. Images courtesy of
Johns Hopkins Hospital/National Institutes of Health.
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repair and when the diagnosis is not known.
We have shown that open repairs of the aorta are well
tolerated in the elective setting and that endovascular
repairs of medium-sized arteries are also well tolerated.10
The preoperative diagnosis allows the surgeon to prepare
for perioperative and intraoperative management. In the
perioperative setting, communication with the anesthesiol-
ogists is a key element in management because it allows for
careful intubation, use of ultrasound-guided vascular ac-
cess, and stringent blood pressure control. Indeed, one in-
dividual survived an abdominal aortic aneurysm repair, only
to die of a central catheter complication during another
hospitalization 10 years later.Intraoperatively, the surgeon should be prepared to deal
with the fragile tissues. Clamping techniques are modiﬁed,
including a more proximal “fall-back position” to avoid
placing vascular clamps on the same location, avoiding a
Rommel tourniquet because it tends to create circumferen-
tial adventitial hematoma, and using external pneumatic
tourniquets to control limbs proximally. Buttressing the su-
tures lines with circumferential individual felt pledgets to
promote hemostasis in aortic repairs has been described.11
In the endovascular setting for arterial embolization in
medium-sized arteries, the surgeon can apply these same prin-
ciples of access vessel management with open exposure
for large diameter sheaths, minimal sheath exchanges, and
circumferential individual pledget reinforcement for closure.10
Table V. Fifty operative procedures classiﬁed according
to preoperative knowledge of vascular Ehlers-Danlos
syndrome (vEDS) diagnosis
Variable
Diagnosis
known
(n ¼ 29),
No. (%)
Diagnosis
not known
(n ¼ 21),
No. (%) Pa
Family history 13 (44.8) 9 (42.9) .890
HI mutation 6 (20.7) 7 (33.3) .314
Open surgical repair 14 (48.3) 17 (81.0) .019
Endovascular procedures 15 (51.7) 4 (19.0) .019
Emergency repairs 12 (41.3) 17 (80.9) .005
Intraoperative death 0 3 (14.2) .036
Postoperative complications 4 (13.7) 13 (61.9) <.001
HI, Haploinsufﬁciency mutations that lead to 50% normal type III collagen
production.
aP value calculated using the Pearson c2 test for categoric data.
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ciﬁc attention to blood pressure control. We have used a
stepwise increase in allowed systolic pressure in aortic pa-
tients, with systolic blood pressure maintained at <90 mm
Hg for the ﬁrst 24 to 48 hours postoperatively, gradually
increasing to normotension on postoperative days 3 to 5.
Because treatment with b-adrenergic blocking agents has
been shown to decrease vascular events in vEDS patients,12
these agents should be considered for blood pressure con-
trol. Other postoperative considerations include adequate
pain management and diligent monitoring and immediate
treatment of constipation because it may lead to bowel
rupture.
With the understanding that diagnosed vEDS patients
can do well with elective surgical repair of arterial pathol-
ogy, it raises the question about the extent these patients
should have ongoing surveillance for vascular diseases, a
topic that is controversial.8 We recommend surveillance
with carotid artery ultrasound scans and noninvasive imag-
ing of the thoracic and abdominal aorta, visceral arteries,
and iliac arteries by using magnetic resonance angiography
(MRA) during the initial evaluation of these patients, fol-
lowed by targeted CT as needed based on vascular pathol-
ogy identiﬁed. The young age of most patients makes
routine use of CT as a surveillance method problematic
due to lifetime radiation exposure issues. Because rare
vascular complications have occurred in patients in their
teenaged years, it is reasonable to obtain a baseline study
before the age of 20 years. Patients with a known vascular
lesion can be monitored in a manner tailored to the lesion
and the patient. However, further data regarding intensity
of surveillance is needed.
In patients without a vascular manifestation, peri-
odic arterial screening is recommended; however, fre-
quency is not known, and further data regarding
intensity of surveillance is needed.2 Without ongoing
surveillance, vascular complications have generally been
described as sudden and catastrophic, and our data sup-
port this statement. It was generally believed that
gradual vascular dilatation, such as seen in Marfansyndrome, was not a feature of vEDS.13 With surveil-
lance, asymptomatic dissections and aneurysms can be
identiﬁed in vEDS patients, and our data suggest that
this arterial pathology can be surgically repaired. Further
research regarding these asymptomatic vascular
anatomic events is needed to determine natural history
and morphology changes that may motivate surgical or
endovascular intervention.
It is imperative that the disease be properly diag-
nosed when encountering peripheral arterial aneurysms
or dissections in a young patient. Features of vEDS,
such as facial characteristics, unexplained bruises, and
translucent or thin skin should be examined, and a his-
tory should be elicited to note clubfoot, dislocations,
or pneumothorax. However, the absence of the facial
appearance or a clinical history suggestive of vEDS
does not rule out the disease, because there are a consid-
erable number of patients without major features
(Fig 1). Obtaining a family history of sudden death
due to unknown causes at a young age or arterial com-
plications is important for identifying possible cases of
vEDS, and referral to a medical geneticist for counseling
and diagnosis is appropriate. Establishing the diagnosis
allows for genetic counseling, proper surveillance to
detect the arterial pathology, and for elective repair plan-
ning by a multidisciplinary team involving vascular
surgeons, cardiac surgeons, interventionists, and medical
geneticists. The correct diagnosis also allows for the
ﬁrst-degree relatives to undergo counseling and testing,
thus identifying asymptomatic vEDS individuals before
they experience a potentially catastrophic event.
The development of medical treatment options, such as
the use of celiprolol,12,14 as well as growing experience
with prophylactic endovascular and open procedures, stand
to improve the prognosis for vEDS. Although the disease is
rare, the morbidity and mortality are signiﬁcant and war-
rant the study of long-term outcomes with contemporary
surgical and medical interventions.
CONCLUSIONS
Establishing the molecular diagnosis of vEDS is imper-
ative to disease management. When surgical repair is indi-
cated, elective repairs offered by a multidisciplinary team
and using surgical techniques applied to address the fragile
tissues are associated with favorable outcomes. This
approach is expected to improve the overall prognosis of
patients with vEDS.
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ciency type, are you still comfortable doing endovascular repair?
Classically we are taught not to. We actually just did one right
before we came here, and we had to do a type A repair and then
we ﬁxed the secondary part with an endograft. But the question
is: Is that a durable procedure? Is that something that is just tem-
porary and then you have to go back in to do a more deﬁnitive
procedure?
Dr Sherene Shalhub. The short answer is we don’t know.
Current recommendations argue against the use of aortic endovas-
cular stent grafts, which is different from angioembolizations.
Thoracic aortic endografts exert external radial force and push
on the abnormal aortic walls; thus, they are not recommended in
the collagen disorders. However, having said that, reviewing the
literature, there are quite a few cases that are reported with success-
ful repair, but their genotype data are not always provided; thus, it
is difﬁcult to extrapolate based on these case reports.
Dr Darling. And a lot of those reports don’t have long-term
results.
Dr Shalhub. That is true.
Dr B. Timothy Baxter (Omaha, Neb). You talked about the
surveillance. I wondered what your recommendations are in termsof interval of surveillance and type of studies to do in these
patients?
Dr Shalhub. The current recommendations have been estab-
lished where they are recommending follow-up for these. Mag-
netic resonance imaging is a perfectly ﬁne modality of
surveillance. In terms of how frequently to surveil them, we do
not know, but are recommending starting at age 20 and surveilling
every 2 to 3 years. If they have abnormalities that are new, they
may warrant closer follow-up to look for interval enlargement or
changes.
Dr Manish Mehta. (Albany, NY). Does the presence of the
haploinsufﬁciency mutation change your management regardless
of the indication that the patient is presenting with?
Dr Shalhub. I would still approach them the same way, but it
may make me feel more comfortable doing an open operation, for
example, as opposed to using an endovascular approach. Our hy-
pothesis was that it makes a difference because the amount of
type III collagen in the tissue is more than the patients with min-
imal mutations. But again, the numbers are small at this stage, so it
is hard to generalize. I am hoping that as we continue to enroll
more patients, we will obtain more information and be able to
make better recommendations.
